Considering the reduced expression of GLAST and altered D-serine release associated with astrocytic dysfunction in schizophrenia, the final question we aim to address concerns the potential role of astrocytes in pharmacological treatment, particularly in the context of precision psychiatry for schizophrenia and TRS. The gene discussed is SLC1A3; the disease is schizophrenia.